Abstract 【Objective】 To investigate the prevalence of nonalcoholic fatty liver disease (NAFLD) in children and adolescents with type 1 diabetes (T1DM) by proton density fat fraction (MRI-PDFF) with MRI and analyze the influencing factors. 【Methods】 A total of 164 children and adolescents with T1DM admitted to Xi'an Tangcheng Hospital from January 2012 to January 2021 were selected and divided into observation group (NAFLD, n=26) and control group (NAFLD, n=138) according to whether NAFLD was combined or not. Univariate and multivariate logistic regression were used to analyze the related influencing factors of adolescent T1DM patients with NAFLD, and to compare the different liver histologic characteristics of children and adolescents with T1DM patients with NAFLD MRI-PDFF.【Results】 Among 164 children and adolescents with T1DM, there were 26 patients with NAFLD. The prevalence of NAFLD was 15.8% (26/164). The proportion of BMI-SDS, HDL, TG, ALT, acanthosis nigricans and MRI-PDFF in the two groups were statistically significant (P<0.05). Multivariate logistic regression analysis showed that BMI SDS and MRI-PDFF were independent predictors of NAFLD in children and adolescents with T1DM (P<0.05). In children and adolescents of F3 hanepatic steatosis with T1DM combined with NAFLD, MRI-PDFF was significantly higher than that of F2, F1, F0 (P<0.05); MRI-PDFF in patients with liver fibrosis at F3 and F4 stages was significantly higher than that in patients with liver fibrosis at F2, F1 and F0 stages, and that in patients with liver fibrosis at F4 stage was significantly higher than that in patients with liver fibrosis at F3 stage (P<0.05). 【Conclusion】 BMI-SDS and MRI-PDFF are independent predictors of NAFLD in children and adolescents with T1DM. MRI-PDFF is helpful to quantitatively evaluate the degree of liver steatosis and the stage of liver fibrosis in NAFLD patients, and has important clinical significance.
LIU Ting,LI Bin-long,LI Yan. Prevalence and Influencing Factors of Nonalcoholic Fatty Liver Disease in Children and Adolescents with Type 1 Diabetes[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(10): 1474-1477.
[1] KWOK R,CHOI K C,WONG G L,et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:a prospective cohort study[J].Gut,2016,65(8):1359-1368.
[2] GU J,LIU S,DU S,et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease:a meta-analysis[J].Eur Radiol,2019,29(7):3564-3573.
[3] ANDERSON E L,HOWE L D,JONES H E,et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents:a systematic review and meta-analysis[J].PLoS One,2015,10(10):e0140908.
[4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病防治指南(2018年版)[J].实用肝脏病杂志,2018,21(2):177-186.
[5] LIAO R,FU Y P,WANG T,et al. Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma:a retrospective cohort study at two centers in China[J].Oncotarget,2017,8(1):1774-1781.
[6] HAN M A,SAOUAF R,AYOUB W,et al. Magnetic resonance imaging and transient elastography in the management of nonalcoholic fatty liver disease (NAFLD) [J].Expert Rev Clin Pharmacol,2017,10(4):379-390.
[7] WANG J H,OU H Y,YEN Y H,et al. Usefulness of controlled attenuation parameter in detecting and monitoring hepatic steatosis with MRI-PDFF as reference[J].Dig Dis Sci,2020,65(5):1512-1519.
[8] BUZZETTI E,PINZANI M,TSOCHATZIS E A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J].Metabolism,2016,65(8):1038-1048.
[9] XING B,ZHAO Y,DONG B,et al. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes:A meta-analysis of randomized controlled trials[J].J Diabetes Investig,2020,11(5):1238-1247.
[10] LEE B W,LEE Y H,PARK C Y,et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus:a position statement of the fatty liver research group of the Korean diabetes association[J].Diabetes Metab J,2020,44(3):382-401.
[11] CUSI K,SANYAL AJ,ZHANG S,et al. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes[J].Diabetes Obes Metab,2017,19(11):1630-1634.
[12] PETIT J M,PEDRO L,GUIU B,et al. Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis[J].Diabet Med,2015,32(12):1648-1651.
2022, Vol. 39 
